James Ian Griffin (James Griffin)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Emergency Department

Chronic Lymphocytic Leukemia

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Jesse Yu, Xiaolin Xu, James Ian Griffin, Qingxin Mu, Rodney J Y Ho
Drug Combination Nanoparticles Containing Gemcitabine and Paclitaxel Enable Orthotopic 4T1 Breast Tumor Regression. Cancers 16 (16) (2024)
Jesse Yu, Xiaolin Xu, James Ian Griffin, Qingxin Mu, Rodney J Y Ho
Drug Combination Nanoparticles Containing Gemcitabine and Paclitaxel Enable Orthotopic 4T1 Breast Tumor Regression. Cancers 16 (16) (2024)
James Ian Griffin, Yan Wu, Qingxin Mu, Xinyan Li, Rodney J Y Ho
Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure. Pharmaceutics 15 (3) (2023)
James Ian Griffin, Yan Wu, Qingxin Mu, Xinyan Li, Rodney J Y Ho
Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure. Pharmaceutics 15 (3) (2023)
James Ian Griffin, Yan Wu, Qingxin Mu, Xinyan Li, Rodney J Y Ho
Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure. Pharmaceutics 15 (3) (2023)